Rapid Finger-Prick test could help shield cancer patients from COVID-19
NCT ID NCT04492410
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a quick finger-prick blood test to see if cancer patients had been infected with COVID-19 in the past. Researchers enrolled 214 adults being treated for cancer. The goal was to find out how many had antibodies, including those without symptoms, to help clinics keep infected and non-infected patients apart and plan safer cancer care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
rapid serological test (finger-prick blood test)
What this could lead to
If successful, this screening method could help cancer clinics quickly identify patients who have had COVID-19, allowing safer separation of infected and non-infected patients during treatment.
What could go wrong
This was a small, completed study focused on measuring infection rates, not on treating disease. The rapid test may be less accurate than standard lab tests, and results may not apply to all cancer patients or settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Antoine Lacassagne
Nice, 06189, France